ROCKET PHARMACEUTICALS, INC. 8-K

What Happened

• Rocket Pharmaceuticals, Inc. announced on April 26, 2026 that it entered into a definitive asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV). The buyer has agreed to pay $180 million in cash at closing.
• The PRV was originally issued in connection with FDA approval of KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell–based gene therapy for pediatric patients with severe leukocyte adhesion deficiency‑I (LAD‑I) due to biallelic ITGB2 variants. The company issued a press release on April 28, 2026 announcing the agreement.

Key Details

• Agreement date: April 26, 2026; press release furnished April 28, 2026 (Exhibit 99.1).
• Purchase price: $180,000,000 payable in cash at closing.
• Closing conditions: customary conditions, including expiration or termination of the Hart‑Scott‑Rodino antitrust waiting period.
• The PRV APA includes customary representations, warranties, covenants and indemnities (with specified limitations); the full agreement will be filed in Rocket’s Form 10‑Q for the quarter ended June 30, 2026.

Why It Matters

• If the sale closes, Rocket will receive a one‑time $180 million cash inflow, which will directly affect the company’s cash position once completed.
• The transaction removes the PRV asset from Rocket’s balance sheet and is subject to regulatory and closing conditions, so investors should watch for updates (closing confirmation and the forthcoming 10‑Q filing containing the full PRV APA).